Springfield, Illinois is currently witnessing a heated legislative debate. With less than two weeks remaining in their spring session, Illinois lawmakers are evaluating a proposal for a new state panel. This panel, termed as the Prescription Drug Affordability Board, is aimed at tackling the high costs associated with prescription drugs. It seeks to analyze whether medications remain out of reach for those in dire need.
The drive to establish this board represents a larger initiative by Democrats to alleviate an ongoing affordability crisis affecting not only Illinois but the entire nation. Yet, critics believe that the panel may only add unnecessary bureaucracy without significantly curbing the prices.
Recently, the bill garnered approval in the House Executive Committee, passing by a vote of 8-4 divided along party lines. It now awaits attention from the full House. Supporters are optimistic about the board’s potential to control escalating drug expenses, a topic intensifying across national discussions. Federal measures under the Biden administration are beginning to show effects this year.
State Representative Nabeela Syed, a Democrat from Palatine, is the primary advocate of the bill. She actively discussed the bill at her campaign office in early October 2024, noting its extensive negotiations during committee discussions. Filed just last week after a previous version faltered in the House last month, the bill proposes a five-member board.
This board, designated by the governor, would scrutinize the costs of most prescription drugs. They would assess whether these prices are exorbitant and set maximum payment limits. Pharmaceutical entities would have the chance to argue their costs before any cap is enforced.
The board’s duties would also extend to ensuring better medication access, particularly in rural and economically disadvantaged areas. Crucially, the legislation links drug prices in Illinois to Medicare’s negotiation abilities under the 2022 Inflation Reduction Act.
Starting this year, Medicare has begun renegotiating reduced rates for ten costly drugs. For instance, Januvia, a diabetes medication, has seen its cost for a 30-day supply drop from $527 to $113. Similarly, Enbrel, meant for rheumatoid arthritis, dropped to $2,355 from $7,106 as reported by the Centers for Medicare & Medicaid Services.
Under Syed’s legislation, the prices negotiated by Medicare would set the upper limits on payments for Illinois consumers, applicable across health plans. However, Medicaid and certain state employee health programs would require separate opt-ins.
Importantly, the board would not be authorized to lower prices on drugs already adjusted through Medicare, though they’d work to make these medicines readily available to needy patients.
Anusha Thotakura, who leads Citizen Action/Illinois, a supporter of Syed’s initiative, referenced an April study by their group indicating a $190 million overpayment on the affected drugs by Illinois. Although opponents contest this, Thotakura insists it highlights a pressing issue. She remarked post-hearing that budget constraints are prompting discussions around service cuts. The focus is also on revenue gaps, particularly regarding overspending.
The proposed board would require members with expertise in healthcare, pharmacy, or clinical medicine but prohibits ties to drug manufacturers or related trade groups. Appointees would serve five-year terms, with initial appointments staggered. Additionally, they’d have assistance from a council consisting of fifteen members. These members would be selected by the governor, the House speaker, Senate president, and minority leaders.
Board rulings might face appeals and judicial scrutiny. Moreover, while the bill mentions potential enforcement by the Illinois attorney general, Syed assures any legal inadequacies could be rectified by the General Assembly and the Legislative Audit Commission.
About twelve states now operate prescription drug affordability boards, though they vary in scope. States such as Colorado, Minnesota, and Maryland—being the pioneer in 2019—have empowered their boards to set payment limits.
The Pharmaceutical Research and Manufacturers of America (PhRMA), opposing the bill, claims that previous boards haven’t resulted in tangible savings for patients. During discussions with the Illinois House committee, Peter Fotos, PhRMA’s deputy VP for state advocacy, argued against applying the Medicare pricing structure at the state level due to inconsistent alignment with state Medicaid programs and other factors.
Ryan Spain, the Deputy Republican leader from Peoria, expressed concerns over increased bureaucracy and pointed out the absence of a supervising state agency. He remarked on the potential challenges if the bill passes since further operational support might be necessary. In response, Syed maintained the board’s independent function. She stipulated an operating budget of $750,000 and rebuffed affiliation with a specific agency.
A Democratic spokesperson for Gov. JB Pritzker stated their office is assessing the proposal but hasn’t disclosed the governor’s stance.
Meanwhile, the Illinois legislature advanced another affordability-focused initiative. The Senate approved a motion banning ‘junk fees’, requiring all advertised prices to encompass mandatory charges. This measure now awaits Pritzker’s signature.